Phage therapy for hard-to-treat lung infection
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a chronic lung infection with Mycobacterium abscessus that does not respond to multiple antibiotics.
- You must agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests a virus-based treatment (bacteriophage) for a chronic joint infection caused by a specific bacteria that hasn't responded to other treatments.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
This study tests a new treatment called a phage cocktail (viruses that kill bacteria) for skin infections caused by bacteria that don't respond well to regular antibiotics. The treatment is applied directly to the wound to see if it's safe and effective.
This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.